Compounds > n,n,n'-trimethyl-n'-(2-hydroxy-3-methyl-5-iodobenzyl)-1,3-propanediamine
Page last updated: 2024-09-03

n,n,n'-trimethyl-n'-(2-hydroxy-3-methyl-5-iodobenzyl)-1,3-propanediamine and Lung Neoplasms

n,n,n'-trimethyl-n'-(2-hydroxy-3-methyl-5-iodobenzyl)-1,3-propanediamine has been researched along with Lung Neoplasms in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19902 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Coupal, JJ; Dillon, ML; Kung, HF; Shih, WJ1
Brandenburg, S; Coupal, JJ; DeLand, FH; Dillon, ML; Domstad, PA; Shih, WJ1

Other Studies

2 other study(ies) available for n,n,n'-trimethyl-n'-(2-hydroxy-3-methyl-5-iodobenzyl)-1,3-propanediamine and Lung Neoplasms

ArticleYear
Application of I-123 HIPDM as a lung imaging agent.
    European journal of nuclear medicine, 1988, Volume: 14, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Bronchogenic; Female; Humans; Iodobenzenes; Lung; Lung Diseases, Obstructive; Lung Neoplasms; Male; Middle Aged; Radionuclide Imaging

1988
Demonstration of pulmonary mass defect by iodine-123 N,N,N'trimethyl-N'[2-hydroxy-3-methyl-5-iodobenzyl]-1,3-propanediamine lung imaging.
    Clinical nuclear medicine, 1986, Volume: 11, Issue:9

    Topics: Aged; Carcinoma, Bronchogenic; Humans; Iodobenzenes; Lung Neoplasms; Male; Radionuclide Imaging

1986